Shisi Pharmaceutical Group (02005): Fenelidone has been approved by the State Drug Administration and registered as an API for use in marketed formulations

Zhitongcaijing · 2d ago

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) announced that the Group's fenelidone has been approved by the China National Drug Administration to register as an active ingredient for use in marketed formulations, and is the second domestic company to be approved.

Fenelidone is mainly used in adult patients with chronic kidney disease associated with type 2 diabetes. It can reduce the risk of continued decline in estimated glomerular filtration rate (eGFR), terminal nephropathy, cardiovascular death, and hospitalization due to heart failure.